Vitamin D Deficiency in Chronic Kidney Disease (CKD) Patients

Chronic Kidney Disease Clinical Trial

Official title:

Response of Secondary Hyperparathyroidism to Paricalcitol Versus Ergocalciferol in Patients With Stage 3 and 4 Chronic Kidney Disease With Vitamin D Deficiency: a Randomized Controlled Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00958451
• Other study ID #: CK0023
• Status: Completed
• Phase: Phase 4
• First received: August 11, 2009
• Last updated: March 23, 2011
• Start date: July 2009
• Est. completion date: January 2011

Study information

• Verified date: August 2009
• Source: Salem Veterans Affairs Medical Center
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Federal Government
• Study type: Interventional

Clinical Trial Summary

This is an open label, single center, randomized, active comparator controlled study, comparing the effects of vitamin D replacement using oral ergocalciferol versus paricalcitol on parathyroid hormone (PTH) levels in patients with stage 3 and 4 CKD and vitamin D deficiency or insufficiency. The purpose of this study is to determine which of these two approaches is more successful.

Description:

This study will enroll chronic kidney disease patients, stage 3 and 4, who have low serum vitamin D levels as defined by K DOQI Guidelines. Patients will be randomized to receive oral daily ergocalciferol or paricalcitol. A total of 80 patients will be enrolled, 40 in the cholecalciferol group and 40 in the paricalcitol group. Outcomes will be assessed as proportion of patients achieving pre-defined changes from baseline and as absolute changes from baseline values. Baseline values will be determined from averaging two consecutive measurements of the variables of interest prior to randomization.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 80
• Est. completion date: January 2011
• Est. primary completion date: January 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Male or female chronic kidney disease patients at least 18 years of age.

2. Patients should be able and willing to provide written informed consent and HIPAA Authorization.

3. Chronic kidney disease stage 3 or 4.

4. Plasma intactPTH level above 75pg/ml.

5. Serum 25 OHD level below 30ng/ml.

6. Negative pregnancy test unless 2 years postmenopausal or with a documented tubal ligation or total hysterectomy.

7. Patients need to be off of any Vitamin analogues or preparations for 4 weeks prior to screening.

Exclusion Criteria:

1. Women who are breast feeding, pregnant, capable of becoming pregnant, and not participating in an acceptable form of birth control.

2. Patients currently participating in a clinical trial with another investigational drug or device or who have receive an investigational drug or device within 30 days of enrollment in this study.

3. Major surgery within one month prior to enrollment or planned surgery while patient is in study (other than dialysis vascular access surgery).

4. Patients who have had a malignancy unless they have received curative treatment and have been disease free for 2 years.

5. Patients with a medical status that the PI decides would preclude participation.

6. Patients on hemodialysis or peritoneal dialysis.

7. Patients with a functional renal transplant.

8. Patients with allergies to study drugs.

9. Patients with acute renal failure with the past 12 weeks.

10. Patients with clinically significant gastrointestinal or liver disease.

11. Patients with active granulomatous disease.

12. Patients with urine calcium:creatinine ratio of more than 0.2.

13. Patients who received vitamin D analogs, calcimimetics, or biphosphonates within 4 weeks before screening. Treatment with any one of these medicines during the study is not permitted.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Chronic Kidney Disease
• Hyperparathyroidism
• Hyperparathyroidism, Secondary
• Kidney Diseases
• Renal Insufficiency, Chronic
• Secondary Hyperparathyroidism
• Vitamin D Deficiency

Intervention

Drug:
• Paricalcitol
Patients will receive 1mcg once daily orally if iPTH is less than 500pg/ml; Patients will receive 2mcg once daily orally if iPTH is more than 500pg/ml. Duration of administration will be 16 weeks.
• Ergocalciferol
If baseline 25 OHD level is less than 5ng/mml: ergocalciferol 50,000 units once a week orally for 12 weeks, then 50,000 units monthly for total duration of 16 weeks. If baseline 25 OHD is between 5 and 15mg/ml: Ergocalciferol 50,000 units once a week orally for 4 weeks, then 50,000 units once a month for total duration of 16 weeks. If baseline 25 OHD level is between 16 and 30ng/ml: Ergocalciferol 50,000 units orally once every 4 weeks for 16 weeks.

Locations

Country	Name	City	State
United States	VA Medical Center	Salem	Virginia

Sponsors (2)

Lead Sponsor	Collaborator
Salem Veterans Affairs Medical Center	Abbott

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To achieve 2 consecutive iPTH measurements with 30% or greater decrease from baseline		2 years	Yes
Secondary	To achieve 25OHD level above 30 ng/ml and change cardiovascular markers		2 years	Yes